Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419219

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419219

APAC Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2032

PUBLISHED:
PAGES: 271 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

Asia-Pacific acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 13.0% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022 the base year of calculation is 2023, and the forecast period is 2024 to 2031.

Market Segmentation

Asia-Pacific Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) Country, (China, India, Japan, Australia, South Korea, Singapore, And Rest Of Asia-Pacific) - Industry Trends and Forecast to 2031.

Overview of Asia-Pacific Acute Myeloid Leukemia Diagnostics Market Dynamics

  • Driver
  • Increasing diagnostic products for leukemia cancer
  • Restraint
  • Late diagnosis and Poor prognosis of leukemia
  • Opportunity
  • Initiatives by government and other authorities for life sciences and funding

Market Players

Some of the major market players in Asia-Pacific acute myeloid leukemia diagnostics market are:

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Abbott
  • Siemens Healthcare GmbH
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • DiaSorin S.p.A.
  • Illumina, Inc.
  • BIOMERIEUX
  • Myriad Genetics, Inc.
  • Quest Diagnostics Incorporated.
  • Bio-Rad Laboratories, Inc.
  • Koninklijke Philips N.V.
  • BD
  • Exact Sciences Corporation
  • Time Medical Holding
  • PlexBio
  • MinFound Medical Systems Co., Ltd
  • Medonica Co. LTD
  • CANON MEDICAL SYSTEMS CORPORATION
  • Sysmex Corporation
Show more

TABLE OF CONTENTS

1 INTRODUCTION 52

  • 1.1 OBJECTIVES OF THE STUDY 52
  • 1.2 MARKET DEFINITION 52
  • 1.3 OVERVIEW OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 52
  • 1.4 LIMITATIONS 54
  • 1.5 MARKETS COVERED 55

2 MARKET SEGMENTATION 58

  • 2.1 MARKETS COVERED 58
  • 2.2 GEOGRAPHICAL SCOPE 59
  • 2.3 YEARS CONSIDERED FOR THE STUDY 60
  • 2.4 CURRENCY AND PRICING 60
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
  • 2.6 MULTIVARIATE MODELLING 64
  • 2.7 PRODUCT TYPE LIFELINE CURVE 64
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
  • 2.9 DBMR MARKET POSITION GRID 66
  • 2.10 MARKET END USER COVERAGE GRID 67
  • 2.11 VENDOR SHARE ANALYSIS 68
  • 2.12 SECONDARY SOURCES 69
  • 2.13 ASSUMPTIONS 69

3 EXECUTIVE SUMMARY 70

4 PREMIUM INSIGHTS 73

  • 4.1 PESTEL ANALYSIS 74
  • 4.2 PORTER'S FIVE FORCES 75
  • 4.3 EPIDEMIOLOGY 76

5 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 77

  • 5.1 REGULATORY SCENARIO IN THE U.S. 77
  • 5.2 REGULATORY SCENARIO IN AUSTRALIA 78
  • 5.3 REGULATORY SCENARIO IN JAPAN 78
  • 5.4 REGULATORY SCENARIO IN CHINA 78

 

6 MARKET OVERVIEW 80

  • 6.1 DRIVERS 82
    • 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 82
    • 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 84
    • 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 84
    • 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 85
  • 6.2 RESTRAINTS 85
    • 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 85
    • 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 86
  • 6.3 OPPORTUNITIES 86
    • 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 86
    • 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 87
    • 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 88
  • 6.4 CHALLENGES 88
    • 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 88
    • 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 89

7 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 90

  • 7.1 OVERVIEW 91
  • 7.2 INSTRUMENTS 94
    • 7.2.1 BIOPSY INSTRUMENTS 95
      • 7.2.1.1 BONE MARROW BIOPSY 95
      • 7.2.1.2 NEEDLE BIOPSY 95
      • 7.2.1.3 SURGICAL BIOPSY 95
      • 7.2.1.4 OTHERS 95
    • 7.2.2 PATHOLOGY-BASED INSTRUMENTS 96
      • 7.2.2.1 PCR INSTRUMENTS 96
      • 7.2.2.2 SLIDE STAINING SYSTEMS 96
      • 7.2.2.3 TISSUE PROCESSING SYSTEMS 96
      • 7.2.2.4 CELL PROCESSORS 96
      • 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 96
    • 7.2.3 IMAGING INSTRUMENTS 97
      • 7.2.3.1 ULTRASOUND SYSTEMS 97
      • 7.2.3.2 CT SYSTEMS 97
      • 7.2.3.3 MRI SYSTEMS 97
      • 7.2.3.4 OTHERS 97
    • 7.2.4 OTHERS 97

 

  • 7.3 CONSUMABLES & ACCESSORIES 98
    • 7.3.1 KITS 99
      • 7.3.1.1 PCR KITS 99
      • 7.3.1.2 DNA POLYMERASE KITS 99
      • 7.3.1.3 NUCLEIC ACID ISOLATION KITS 99
      • 7.3.1.4 OTHERS 99
    • 7.3.2 REAGENTS 100
      • 7.3.2.1 ASSAYS 100
      • 7.3.2.2 BUFFERS 100
      • 7.3.2.3 PRIMERS 100
      • 7.3.2.4 OTHERS 100
    • 7.3.3 PROBES 101
    • 7.3.4 OTHER CONSUMABLES 101

8 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 102

  • 8.1 OVERVIEW 103
  • 8.2 BLOOD TEST 106
    • 8.2.1 COMPLETE BLOOD COUNT (CBC) 107
    • 8.2.2 BLOOD CHEMISTRY TESTS 107
    • 8.2.3 OTHERS 107
  • 8.3 IMAGING TEST 108
    • 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 108
    • 8.3.2 MRI 108
    • 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 109
    • 8.3.4 OTHERS 109
  • 8.4 BONE MARROW TESTS 109
    • 8.4.1 BONE MARROW ASPIRATE 110
    • 8.4.2 BONE MARROW BIOPSY 110
    • 8.4.3 OTHERS 110
  • 8.5 GENETIC TESTS 110
    • 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 111
    • 8.5.2 KARYOTYPING 111
    • 8.5.3 OTHERS 111
  • 8.6 BIOMARKER TEST 112
    • 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
    • 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
    • 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113

 

  • 8.7 IMMUNOPHENOTYPING 113
    • 8.7.1 FLOW CYTOMETRY 113
    • 8.7.2 IMMUNOHISTOCHEMISTRY 114
    • 8.7.3 OTHERS 114
  • 8.8 OTHERS 114

9 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 115

  • 9.1 OVERVIEW 116
  • 9.2 MYELOBLASTIC (M0) 119
  • 9.3 MYELOBLASTIC (M1) 120
  • 9.4 MYELOBLASTIC (M2) 120
  • 9.5 PROMYELOCYTIC (M3) 121
  • 9.6 MYELOMONOCYTIC (M4) 121
  • 9.7 MONOCYTIC (M5) 122
  • 9.8 ERYTHROLEUKEMIA (M6) 122
  • 9.9 MEGAKARYOCYTIC (M7) 123

10 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 124

  • 10.1 OVERVIEW 125
  • 10.2 65 AND ABOVE 128
  • 10.3 30-65 129
  • 10.4 BELOW 21 129
  • 10.5 21-29 130

11 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 131

  • 11.1 OVERVIEW 132
  • 11.2 MALE 135
  • 11.3 FEMALE 136

12 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 137

  • 12.1 OVERVIEW 138
  • 12.2 HOSPITALS 141
  • 12.3 ASSOCIATED LABS 142
  • 12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 142
  • 12.5 DIAGNOSTIC IMAGING CENTERS 143
  • 12.6 CANCER RESEARCH INSTITUTES 143
  • 12.7 OTHERS 144

 

13 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 145

  • 13.1 OVERVIEW 146
  • 13.2 DIRECT TENDER 149
  • 13.3 RETAIL SALES 150

14 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 151

  • 14.1 ASIA-PACIFIC 154
    • 14.1.1 CHINA 160
    • 14.1.2 JAPAN 165
    • 14.1.3 INDIA 170
    • 14.1.4 AUSTRALIA 175
    • 14.1.5 SOUTH KOREA 180
    • 14.1.6 INDONESIA 185
    • 14.1.7 PHILIPPINES 190
    • 14.1.8 THAILAND 195
    • 14.1.9 MALAYSIA 200
    • 14.1.10 VIETNAM 205
    • 14.1.11 SINGAPORE 211
    • 14.1.12 REST OF ASIA-PACIFIC 216

15 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 217

  • 15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 217

16 SWOT ANALYSIS 218

17 COMPANY PROFILES 219

  • 17.1 CANON MEDICAL SYSTEMS CORPORATION. 219
    • 17.1.1 COMPANY SNAPSHOT 219
    • 17.1.2 REVENUE ANALYSIS 220
    • 17.1.3 COMPANY SHARE ANALYSIS 220
    • 17.1.4 PRODUCT PORTFOLIO 221
    • 17.1.5 RECENT DEVELOPMENT 221
  • 17.2 SYSMEX CORPORATION 222
    • 17.2.1 COMPANY SNAPSHOT 222
    • 17.2.2 REVENUE ANALYSIS 222
    • 17.2.3 COMPANY SHARE ANALYSIS 223
    • 17.2.4 PRODUCT PORTFOLIO 223
    • 17.2.5 RECENT DEVELOPMENT 223

 

  • 17.3 EPIGENOMICS AG. 224
    • 17.3.1 COMPANY SNAPSHOT 224
    • 17.3.2 REVENUE ANALYSIS 224
    • 17.3.3 COMPANY SHARE ANALYSIS 225
    • 17.3.4 PRODUCT PORTFOLIO 225
    • 17.3.5 RECENT DEVELOPMENT 226
  • 17.4 MYRIAD GENETICS, INC. 227
    • 17.4.1 COMPANY SNAPSHOT 227
    • 17.4.2 REVENUE ANALYSIS 227
    • 17.4.3 COMPANY SHARE ANALYSIS 228
    • 17.4.4 PRODUCT PORTFOLIO 228
    • 17.4.5 RECENT DEVELOPMENT 229
  • 17.5 F. HOFFMANN- LA ROCHE LTD 230
    • 17.5.1 COMPANY SNAPSHOT 230
    • 17.5.2 REVENUE ANALYSIS 230
    • 17.5.3 COMPANY SHARE ANALYSIS 231
    • 17.5.4 PRODUCT PORTFOLIO 231
    • 17.5.5 RECENT DEVELOPMENT 231
  • 17.6 ABBOTT 232
    • 17.6.1 COMPANY SNAPSHOT 232
    • 17.6.2 REVENUE ANALYSIS 232
    • 17.6.3 PRODUCT PORTFOLIO 233
    • 17.6.4 RECENT DEVELOPMENT 233
  • 17.7 AGILENT TECHNOLOGIES, INC. 234
    • 17.7.1 COMPANY SNAPSHOT 234
    • 17.7.2 REVENUE ANALYSIS 234
    • 17.7.3 PRODUCT PORTFOLIO 235
    • 17.7.4 RECENT DEVELOPMENT 235
  • 17.8 BD 236
    • 17.8.1 COMPANY SNAPSHOT 236
    • 17.8.2 REVENUE ANALYSIS 236
    • 17.8.3 PRODUCT PORTFOLIO 237
    • 17.8.4 RECENT DEVELOPMENT 237
  • 17.9 BIOMERIEUX 238
    • 17.9.1 COMPANY SNAPSHOT 238
    • 17.9.2 PRODUCT PORTFOLIO 238
    • 17.9.3 RECENT DEVELOPMENT 238

 

  • 17.10 BIO-RAD LABORATORIES, INC. 239
    • 17.10.1 COMPANY SNAPSHOT 239
    • 17.10.2 REVENUE ANALYSIS 239
    • 17.10.3 PRODUCT PORTFOLIO 240
    • 17.10.4 RECENT DEVELOPMENT 240
  • 17.11 DIASORIN S.P.A. 241
    • 17.11.1 COMPANY SNAPSHOT 241
    • 17.11.2 REVENUE ANALYSIS 241
    • 17.11.3 PRODUCT PORTFOLIO 242
    • 17.11.4 RECENT DEVELOPMENTS 242
  • 17.12 EXACT SCIENCES CORPORATION 243
    • 17.12.1 COMPANY SNAPSHOT 243
    • 17.12.2 REVENUE ANALYSIS 243
    • 17.12.3 PRODUCT PORTFOLIO 244
    • 17.12.4 RECENT DEVELOPMENTS 244
  • 17.13 HOLOGIC INC. 245
    • 17.13.1 COMPANY SNAPSHOT 245
    • 17.13.2 REVENUE ANALYSIS 245
    • 17.13.3 PRODUCT PORTFOLIO 246
    • 17.13.4 RECENT DEVELOPMENT 246
  • 17.14 ILLUMINA, INC. 247
    • 17.14.1 COMPANY SNAPSHOT 247
    • 17.14.2 REVENUE ANALYSIS 247
    • 17.14.3 PRODUCT PORTFOLIO 248
    • 17.14.4 RECENT DEVELOPMENT 248
  • 17.15 KONINKLIJKE PHILIPS N.V. 249
    • 17.15.1 COMPANY SNAPSHOT 249
    • 17.15.2 REVENUE ANALYSIS 249
    • 17.15.3 PRODUCT PORTFOLIO 250
    • 17.15.4 RECENT DEVELOPMENT 250
  • 17.16 MEDONICA CO. LTD 251
    • 17.16.1 COMPANY SNAPSHOT 251
    • 17.16.2 PRODUCT PORTFOLIO 251
    • 17.16.3 RECENT DEVELOPMENT 251
  • 17.17 MINFOUND MEDICAL SYSTEMS CO., LTD 252
    • 17.17.1 COMPANY SNAPSHOT 252
    • 17.17.2 PRODUCT PORTFOLIO 252
    • 17.17.3 RECENT DEVELOPMENT 253

 

  • 17.18 PLEXBIO 254
    • 17.18.1 COMPANY SNAPSHOT 254
    • 17.18.2 PRODUCT PORTFOLIO 254
    • 17.18.3 RECENT DEVELOPMENTS 254
  • 17.19 QIAGEN 255
    • 17.19.1 COMPANY SNAPSHOT 255
    • 17.19.2 REVENUE ANALYSIS 255
    • 17.19.3 PRODUCT PORTFOLIO 256
    • 17.19.4 RECENT DEVELOPMENTS 256
  • 17.20 QUEST DIAGNOSTICS INCORPORATED 257
    • 17.20.1 COMPANY SNAPSHOT 257
    • 17.20.2 REVENUE ANALYSIS 257
    • 17.20.3 PRODUCT PORTFOLIO 258
    • 17.20.4 RECENT DEVELOPMENTS 258
  • 17.21 SIEMENS HEALTHCARE GMBH 259
    • 17.21.1 COMPANY SNAPSHOT 259
    • 17.21.2 REVENUE ANALYSIS 259
    • 17.21.3 PRODUCT PORTFOLIO 260
    • 17.21.4 RECENT DEVELOPMENT 260
  • 17.22 SONIC HEALTHCARE 261
    • 17.22.1 COMPANY SNAPSHOT 261
    • 17.22.2 PRODUCT PORTFOLIO 261
    • 17.22.3 RECENT DEVELOPMENT 261
  • 17.23 STERNMED GMBH 262
    • 17.23.1 COMPANY SNAPSHOT 262
    • 17.23.2 PRODUCT PORTFOLIO 262
    • 17.23.3 RECENT DEVELOPMENTS 262
  • 17.24 THERMO FISHER SCIENTIFIC INC. 263
    • 17.24.1 COMPANY SNAPSHOT 263
    • 17.24.2 REVENUE ANALYSIS 263
    • 17.24.3 PRODUCT PORTFOLIO 264
    • 17.24.4 RECENT DEVELOPMENT 264
  • 17.25 TIME MEDICAL HOLDING 265
    • 17.25.1 COMPANY SNAPSHOT 265
    • 17.25.2 PRODUCT PORTFOLIO 265
    • 17.25.3 RECENT DEVELOPMENT 266

18 QUESTIONNAIRE 267

19 RELATED REPORTS 271

Show more

LIST OF TABLES

  • TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 64
  • TABLE 2 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 71
  • TABLE 3 ASIA PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 71
  • TABLE 4 ASIA PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 71
  • TABLE 5 ASIA PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 72
  • TABLE 6 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 73
  • TABLE 7 ASIA PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 74
  • TABLE 8 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 75
  • TABLE 9 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 75
  • TABLE 10 ASIA PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 76
  • TABLE 11 ASIA PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 77
  • TABLE 12 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 83
  • TABLE 13 ASIA PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 83
  • TABLE 14 ASIA PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 84
  • TABLE 15 ASIA PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 85
  • TABLE 16 ASIA PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 85
  • TABLE 17 ASIA PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 86
  • TABLE 18 ASIA PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 86
  • TABLE 19 ASIA PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 87
  • TABLE 20 ASIA PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 88
  • TABLE 21 ASIA PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 89
  • TABLE 22 ASIA PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 89
  • TABLE 23 ASIA PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 90
  • TABLE 24 ASIA PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 90
  • TABLE 25 ASIA PACIFIC OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 91
  • TABLE 26 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 96
  • TABLE 27 ASIA PACIFIC MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 96
  • TABLE 28 ASIA PACIFIC MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 97
  • TABLE 29 ASIA PACIFIC MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 97
  • TABLE 30 ASIA PACIFIC PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 98
  • TABLE 31 ASIA PACIFIC MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 98
  • TABLE 32 ASIA PACIFIC MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 99
  • TABLE 33 ASIA PACIFIC ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 99
  • TABLE 34 ASIA PACIFIC MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 100
  • TABLE 35 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 105
  • TABLE 36 ASIA PACIFIC 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 105
  • TABLE 37 ASIA PACIFIC 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 106
  • TABLE 38 ASIA PACIFIC BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 106
  • TABLE 39 ASIA PACIFIC 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 107
  • TABLE 40 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 112
  • TABLE 41 ASIA PACIFIC MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 112
  • TABLE 42 ASIA PACIFIC FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 113
  • TABLE 43 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 118
  • TABLE 44 ASIA PACIFIC HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 118
  • TABLE 45 ASIA PACIFIC ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 119
  • TABLE 46 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 119
  • TABLE 47 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 120
  • TABLE 48 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 120
  • TABLE 49 ASIA PACIFIC OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 121
  • TABLE 50 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 126
  • TABLE 51 ASIA PACIFIC DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 126
  • TABLE 52 ASIA PACIFIC RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 127
  • TABLE 53 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 131
  • TABLE 54 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 55 ASIA-PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 56 ASIA-PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 57 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 58 ASIA-PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 59 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 60 ASIA-PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 61 ASIA-PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 62 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 63 ASIA-PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 64 ASIA-PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
  • TABLE 65 ASIA-PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
  • TABLE 66 ASIA-PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
  • TABLE 67 ASIA-PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
  • TABLE 68 ASIA-PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 135
  • TABLE 69 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 135
  • TABLE 70 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 135
  • TABLE 71 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 135
  • TABLE 72 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 136
  • TABLE 73 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 136
  • TABLE 74 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 75 CHINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 76 CHINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 77 CHINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 78 CHINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 79 CHINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 80 CHINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 81 CHINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 82 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 83 CHINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 84 CHINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 85 CHINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 86 CHINA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 140
  • TABLE 87 CHINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 140
  • TABLE 88 CHINA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 140
  • TABLE 89 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 140
  • TABLE 90 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 141
  • TABLE 91 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 141
  • TABLE 92 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 141
  • TABLE 93 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 141
  • TABLE 94 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 95 JAPAN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 96 JAPAN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 97 JAPAN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 98 JAPAN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 99 JAPAN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 100 JAPAN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 101 JAPAN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 102 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 103 JAPAN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 104 JAPAN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 105 JAPAN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 106 JAPAN GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 107 JAPAN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 108 JAPAN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 109 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 145
  • TABLE 110 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 146
  • TABLE 111 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 146
  • TABLE 112 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 146
  • TABLE 113 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 146
  • TABLE 114 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 115 INDIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 116 INDIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 117 INDIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 118 INDIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 119 INDIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 120 INDIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 121 INDIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 122 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 123 INDIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 124 INDIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 125 INDIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 126 INDIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 150
  • TABLE 127 INDIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 150
  • TABLE 128 INDIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 150
  • TABLE 129 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 150
  • TABLE 130 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 151
  • TABLE 131 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 151
  • TABLE 132 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 151
  • TABLE 133 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 151
  • TABLE 134 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 135 AUSTRALIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 136 AUSTRALIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 137 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 138 AUSTRALIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 139 AUSTRALIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 140 AUSTRALIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 141 AUSTRALIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 142 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 143 AUSTRALIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 144 AUSTRALIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 145 AUSTRALIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 146 AUSTRALIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 155
  • TABLE 147 AUSTRALIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 155
  • TABLE 148 AUSTRALIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 155
  • TABLE 149 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 155
  • TABLE 150 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 156
  • TABLE 151 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 156
  • TABLE 152 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 156
  • TABLE 153 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 156
  • TABLE 154 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 155 SOUTH KOREA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 156 SOUTH KOREA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 157 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 158 SOUTH KOREA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 159 SOUTH KOREA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 160 SOUTH KOREA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 161 SOUTH KOREA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 162 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 163 SOUTH KOREA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 164 SOUTH KOREA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 165 SOUTH KOREA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 166 SOUTH KOREA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 167 SOUTH KOREA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 168 SOUTH KOREA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 169 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 170 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 161
  • TABLE 171 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 161
  • TABLE 172 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 161
  • TABLE 173 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 161
  • TABLE 174 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 175 INDONESIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 176 INDONESIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 177 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 178 INDONESIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 179 INDONESIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 180 INDONESIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 181 INDONESIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 182 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 183 INDONESIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 184 INDONESIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 185 INDONESIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 186 INDONESIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 187 INDONESIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 188 INDONESIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 189 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 190 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 166
  • TABLE 191 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 166
  • TABLE 192 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 166
  • TABLE 193 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 166
  • TABLE 194 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 195 PHILIPPINES INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 196 PHILIPPINES BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 197 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 198 PHILIPPINES IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 199 PHILIPPINES CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 200 PHILIPPINES KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 201 PHILIPPINES REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 202 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 203 PHILIPPINES BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 204 PHILIPPINES IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 205 PHILIPPINES BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 206 PHILIPPINES GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 207 PHILIPPINES BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 208 PHILIPPINES IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 209 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 210 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 171
  • TABLE 211 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 171
  • TABLE 212 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 171
  • TABLE 213 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 171
  • TABLE 214 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 215 THAILAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 216 THAILAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 217 THAILAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 218 THAILAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 219 THAILAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 220 THAILAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 221 THAILAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 222 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 223 THAILAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 224 THAILAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 225 THAILAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 226 THAILAND GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 227 THAILAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 228 THAILAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 229 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 230 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 176
  • TABLE 231 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 176
  • TABLE 232 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 176
  • TABLE 233 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 176
  • TABLE 234 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 235 MALAYSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 236 MALAYSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 237 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 238 MALAYSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 239 MALAYSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 240 MALAYSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 241 MALAYSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 242 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 179
  • TABLE 243 MALAYSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 179
  • TABLE 244 MALAYSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 179
  • TABLE 245 MALAYSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 179
  • TABLE 246 MALAYSIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 247 MALAYSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 248 MALAYSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 249 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 180

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 35
  • FIGURE 2 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION 38
  • FIGURE 3 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS 39
  • FIGURE 4 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 40
  • FIGURE 5 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 40
  • FIGURE 6 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 42
  • FIGURE 7 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 43
  • FIGURE 8 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 44
  • FIGURE 9 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 45
  • FIGURE 10 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 49
  • FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 50
  • FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031 50
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 58
  • FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 60
  • FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 60
  • FIGURE 16 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023 68
  • FIGURE 17 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 69
  • FIGURE 18 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 69
  • FIGURE 19 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 70
  • FIGURE 20 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023 80
  • FIGURE 21 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION) 81
  • FIGURE 22 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031) 81
  • FIGURE 23 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 82
  • FIGURE 24 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023 93
  • FIGURE 25 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION) 94
  • FIGURE 26 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031) 94
  • FIGURE 27 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 95
  • FIGURE 28 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023 102
  • FIGURE 29 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 103
  • FIGURE 30 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031) 103
  • FIGURE 31 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 104
  • FIGURE 32 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023 109
  • FIGURE 33 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION) 110
  • FIGURE 34 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031) 110
  • FIGURE 35 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 111
  • FIGURE 36 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023 115
  • FIGURE 37 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION) 116
  • FIGURE 38 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031) 116
  • FIGURE 39 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 117
  • FIGURE 40 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023 123
  • FIGURE 41 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 124
  • FIGURE 42 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 124
  • FIGURE 43 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 125
  • FIGURE 44 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023) 129
  • FIGURE 45 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%) 194
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!